Targeting LncRNA ‐Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Xiuying He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Neuralgia, RNA, Long Noncoding. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan Province of China, Sichuan University Innovation Research Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
Neuropathic pain (NP) is a debilitating condition characterized by chronic pain resulting from nerve damage or lesion. Despite the ongoing efforts of clinically defining NP, its distinctive mechanisms that lead to various NP phenotypes remain unresolved.
Methods
Using a spared nerve injury (SNI) model, we investigated the mechanisms underlying the development of NP caused by injury in the peripheral nerves. With CRISPR‐Cas9‐mediated knockout and virus‐mediated overexpression strategies, we investigated the role of LncRNA Vof16 (abbreviated as Vof16) during SNI‐induced NP.
Results
Our results revealed that SNI led to the downregulation of Vof16 expression in spinal dorsal horn (SDH) of lumbar enlargement. This was evidently confirmed when we disrupted the expression of Vof16 in SNI rats of which we observed exacerbation of hyperalgesia; while overexpressing it alleviated the pain.
Conclusion
Our findings suggest that Vof16 plays a crucial role in maintaining normal sensory function in healthy states and a protective shield against NP following peripheral nerve injury. We therefore propose Vof16 as a new therapeutic target for alleviating NP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
- Institute of Neurological Disease, West China Hospital, Sichuan University, Chengdu, China.
- State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
- Department of Basic Medicine, Medical School, Kunming University of Science and Technology, Kunming, China.
- School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
ORCID-Profile: Xiuying He, Tinghua Wang
Förderung
- Natural Science Foundation of Sichuan Province of China
- Sichuan University Innovation Research Project
- National Natural Science Foundation of China
- Key Research and Development Program of Sichuan Science and Technology Agency
Zitieren
APA
He, X., Mauki, D. H., Zhao, X., Dai, S., Yang, H., Zheng, Y., Xia, Q., Wang, R., & Wang, T. (2025). Targeting LncRNA ‐Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70241
Vancouver
He X, Mauki DH, Zhao X, Dai S, Yang H, Zheng Y, et al. Targeting LncRNA ‐Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70241
BibTeX
@article{He2025,
author = {He, Xiuying and Mauki, David H and Zhao, Xiaoming and Dai, Songyu and Yang, Huisi and Zheng, Yuexiang and Xia, Qingjie and Wang, Rurong and Wang, Tinghua},
title = {Targeting LncRNA ‐Vof16: A Novel Therapeutic Strategy for Neuropathic Pain Relief},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70241}
}
EUVIMED